Alexandre Corthay

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2164496/publications.pdf

Version: 2024-02-01

51 papers	3,350 citations	218381 26 h-index	243296 44 g-index
57 all docs	57 docs citations	57 times ranked	5818 citing authors

#	Article	IF	Citations
1	How do Regulatory T Cells Work?. Scandinavian Journal of Immunology, 2009, 70, 326-336.	1.3	497
2	Primary Antitumor Immune Response Mediated by CD4+ T Cells. Immunity, 2005, 22, 371-383.	6.6	383
3	Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nature Communications, 2011, 2, 240.	5.8	251
4	Immune Cell Composition in Human Non-small Cell Lung Cancer. Frontiers in Immunology, 2018, 9, 3101.	2.2	202
5	Does the Immune System Naturally Protect Against Cancer?. Frontiers in Immunology, 2014, 5, 197.	2.2	183
6	How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?. Frontiers in Immunology, 2014, 5, 174.	2.2	166
7	Toll-Like Receptor Ligands and Interferon-Î³ Synergize for Induction of Antitumor M1 Macrophages. Frontiers in Immunology, 2017, 8, 1383.	2.2	166
8	Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. European Journal of Immunology, 1998, 28, 2580-2590.	1.6	156
9	A Three-cell Model for Activation of NaÃ¯ve T Helper Cells. Scandinavian Journal of Immunology, 2006, 64, 93-96.	1.3	103
10	Collagen-induced arthritis development requires Î±Î² T cells but not Î³Î´ T cells: studies with T cell-deficient (TCR mutant) mice. International Immunology, 1999, 11, 1065-1073.	1.8	88
11	Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation. Frontiers in Immunology, 2018, 9, 2520.	2.2	86
12	Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering anIn SituInflammatory Immune Response. Cancer Research, 2016, 76, 6864-6876.	0.4	77
13	Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells. OncoImmunology, 2016, 5, e1039763.	2.1	77
14	A model for cancer-suppressive inflammation. OncoImmunology, 2012, 1, 1146-1155.	2.1	64
15	Monoclonal Antibodies Produced by Muscle after Plasmid Injection and Electroporation. Molecular Therapy, 2004, 9, 328-336.	3.7	63
16	CD4+ T-cellâ€“Mediated Rejection of MHC Class IIâ€“Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs. Cancer Research, 2018, 78, 4573-4585.	0.4	61
17	T lymphocytes are not required for the spontaneous development of entheseal ossification leading to marginal ankylosis in the DBA/1 mouse. Arthritis and Rheumatism, 2000, 43, 844.	6.7	57
18	Secretion of Tumor-Specific Antigen by Myeloma Cells Is Required for Cancer Immunosurveillance by CD4+ T Cells. Cancer Research, 2009, 69, 5901-5907.	0.4	49

#	Article	IF	Citations
19	Systemic Autoimmune Disease Caused by Autoreactive B Cells That Receive Chronic Help from Ig V Region-Specific T Cells. Journal of Immunology, 2005, 175, 2391-2400.	0.4	48
20	Structural characterization of bioactive heteropolysaccharides from the medicinal fungus Inonotus obliquus (Chaga). Carbohydrate Polymers, 2018, 185, 27-40.	5.1	48
21	Evaluation of the Percentage of Peripheral T Cells with Two Different T Cell Receptor Î±-Chains and of their Potential Role in Autoimmunity. Journal of Autoimmunity, 2001, 16, 423-429.	3.0	44
22	Role of gamma/delta T cell receptor-expressing lymphocytes in cutaneous infection caused by Staphylococcus aureus. Clinical and Experimental Immunology, 2003, 132, 209-215.	1.1	42
23	Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood, 2012, 119, 2176-2177.	0.6	41
24	Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood, 2003, 102, 605-612.	0.6	39
25	Role of glycopeptide-specific T cells in collagen-induced arthritis: an example how Dost-translational modification of proteins Gay be involved in autoimmune disease. Annals of Medicine, 2001, 33, 456-465.	1.5	37
26	Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics. Cancer Treatment Reviews, 2018, 63, 79-95.	3.4	34
27	The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed. Frontiers in Immunology, 2021, 12, 764596.	2.2	31
28	Poly(I:C)-Encapsulating Nanoparticles Enhance Innate Immune Responses to the Tuberculosis Vaccine Bacille Calmetteâ€“GuÃ©rin (BCG) via Synergistic Activation of Innate Immune Receptors. Molecular Pharmaceutics, 2017, 14, 4098-4112.	2.3	28
29	Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models. Communications Biology, 2020, 3, 196.	2.0	27
30	SH2D2A Modulates T Cell Mediated Protection to a B Cell Derived Tumor in Transgenic Mice. PLoS ONE, 2012, 7, e48239.	1.1	23
31	Isoform-specific regulation of immune cell reactivity by the catalytic subunit of protein kinase A (PKA). Cellular Signalling, 2009, 21, 274-281.	1.7	21
32	Coupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated Immunity. Frontiers in Immunology, 2016, 7, 167.	2.2	16
33	Antibody combinations for optimized staining of macrophages in human lung tumours. Scandinavian Journal of Immunology, 2020, 92, e12889.	1.3	16
34	CD4+ T Cells Cooperate With Macrophages for Specific Elimination of MHC Class II-Negative Cancer Cells. , 2007, 590, 195-208.		15
35	Rituximab efficiently depletes B cells in lung tumorsÂand normal lung tissue. F1000Research, 2016, 5, 38.	0.8	15
36	Molecular profiling of tumor-specific T_H1 cells activated in vivo. OncoImmunology, 2013, 2, e24383.	2.1	13

#	Article	IF	Citations
37	Generation and Functional In Vitro Analysis of Semliki Forest Virus Vectors Encoding TNF-Î± and IFN-Î³. Frontiers in Immunology, 2017, 8, 1667.	2.2	13
38	Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Cancer Immunology, Immunotherapy, 2004, 53, 759-69.	2.0	11
39	Is Secretion of Tumourâ€specific Antigen Important for Cancer Eradication by CD4⁺ T Cells? â€“ Implications for Cancer Immunotherapy by Adoptive T Cell Transfer. Scandinavian Journal of Immunology, 2011, 73, 527-530.	1.3	11
40	Immunological Tolerance. Part I of a Report of a Workshop on Foundational Concepts of Immune Regulation. Scandinavian Journal of Immunology, 2017, 85, 84-94.	1.3	11
41	Multi-staining registration of large histology images. , 2017, , .		9
42	Tackling cancer cell dormancy: Insights from immune models, and transplantation. Seminars in Cancer Biology, 2022, 78, 5-16.	4.3	9
43	The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases. Scandinavian Journal of Immunology, 2020, 92, e12893.	1.3	6
44	Immune Class Regulation and Its Medical Significance Part II of a Report of a Workshop on Foundational Concepts of Immune Regulation. Scandinavian Journal of Immunology, 2017, 85, 242-250.	1.3	4
45	The Matrigel Cytokine Assay. Protocol Exchange, 0, , .	0.3	2
46	Reactive Species from Two-Signal Activated Macrophages Interfere with Their Oxygen Consumption Measurements. Antioxidants, 2021, 10, 1149.	2.2	1
47	Cytokine profile of successful cancer immunosurveillance mediated by tumor-specific CD4+ T cells. Cytokine, 2009, 48, 48.	1.4	0
48	CS14-2. A cancer-protective role of inflammation. Cytokine, 2011, 56, 101.	1.4	0
49	Inflammatory Biomarkers for Cancer. , 2017, , 241-257.		0
50	Spatial Analysis For Histopathology: A Statistical Approach. , 2022, , .		0
51	Immunology according to Dembic: Preserving integrity is key. Scandinavian Journal of Immunology, 2022, 95, e13173.	1.3	0